02.15.19
Ingevity Corporation has completed its acquisition of the Capa caprolactone division of Perstorp Holding AB for a cash purchase price of €578.9 million ($652.5 million).
Capa is the global market leader in the production and commercialization of caprolactone and high-value downstream derivatives, including caprolactone polyols, caprolactone thermoplastics, caprolactone lactides, and hexanediol (HDO). The division’s products are key components in adhesives, bioplastics, coatings, elastomers and resins. The business operates a manufacturing facility in Warrington, England, UK, and employs approximately 100 employees. Ingevity will include the business in the company’s Performance Chemicals segment and report revenues as “Engineered Polymers.”
“The Capa division is a strong, market-leading business focused on high-growth end-use applications and is an excellent fit with Ingevity’s business model and capabilities,” said Michael Wilson, Ingevity president and CEO.
Capa is the global market leader in the production and commercialization of caprolactone and high-value downstream derivatives, including caprolactone polyols, caprolactone thermoplastics, caprolactone lactides, and hexanediol (HDO). The division’s products are key components in adhesives, bioplastics, coatings, elastomers and resins. The business operates a manufacturing facility in Warrington, England, UK, and employs approximately 100 employees. Ingevity will include the business in the company’s Performance Chemicals segment and report revenues as “Engineered Polymers.”
“The Capa division is a strong, market-leading business focused on high-growth end-use applications and is an excellent fit with Ingevity’s business model and capabilities,” said Michael Wilson, Ingevity president and CEO.